Vanguard Capital Management
DFTX

Vanguard Capital Management’s Definium Therapeutics DFTX Stock Holding History

Vanguard Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.9M Buy
1,486,454
+389,476
+36% +$9.62M ﹤0.01% 1755
2026
Q1 		$20.7M Buy
+1,096,978
New +$18.6M ﹤0.01% 2324

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Capital Management's DFTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Definium Therapeutics (DFTX) stake by 36% in Q2 2026, buying an estimated $9.62M and bringing the position to 1,486,454 shares worth $69.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

Vanguard Capital Management first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 359 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Vanguard Capital Management held 1,486,454 shares of Definium Therapeutics worth $69.9M as of Q2 2026.
  • Vanguard Capital Management bought 389,476 Definium Therapeutics shares in Q2 2026, an estimated $9.62M.
  • Definium Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1755 holding.
  • Vanguard Capital Management first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 359 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.